Debby Garbato

2 months ago | drugstorenews.com | Debby Garbato

According to IQVIA, U.S. sales of liraglutide injection, 6 mg/mL, were approximately $1.3 billion in the 12 months ending October 2024. According to IQVIA, U.S. sales of liraglutide injection, 6 mg/mL, were approximately $1.3 billion in the 12 months ending October 2024. In 2025, the number of generic drug manufacturers gaining FDA approvals and launching biosimilars and GLP-1 drugs should significantly increase, along with those companies developing generics in other promising areas.

2 months ago | drugstorenews.com | Debby Garbato

According to IQVIA, U.S. sales of liraglutide injection, 6 mg/mL, were approximately $1.3 billion in the 12 months ending October 2024. According to IQVIA, U.S. sales of liraglutide injection, 6 mg/mL, were approximately $1.3 billion in the 12 months ending October 2024. In 2025, the number of generic drug manufacturers gaining FDA approvals and launching biosimilars and GLP-1 drugs should significantly increase, along with those companies developing generics in other promising areas.